Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Director | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,762 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 10,000 · Balance 23,762 F1: Grant of restricted stock, which vest on July 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock, which vest on July 28, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 30, 2026 20:31 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-025075 · rdgdoc.xml · nonDerivative · entry 1 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,762 F1 · shares: Grant of restricted stock, which vest on July 28, 2027. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:06 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030632 · rdgdoc.xml · nonDerivative · entry 1 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,762 F1 · shares: Grant of restricted stock, which vest on October 3, 2026. Read SEC document |
| November 06, 2024 Filed Nov 9, 2024 01:34 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Shares | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-24-000762 · form4.xml · nonDerivative · entry 1 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,762 F1 · security: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting. F1 · shares: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting. F1 · ownership.direct: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting. F1 · ownership.nature: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 23:39 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Shares | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-23-000301 · form4.xml · nonDerivative · entry 1 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,262 F1 · shares: Grant of restricted shares, which vest as follows: 1/3 on August 11, 2024, with the remaining restricted shares vesting in eight equal installments every three months beginning on November 11, 2024. F2 · balance_after: Reflects 1-for-20 reverse stock split effected by the Issuer on January 6, 2023. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 22:40 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerCommon Stock | 187,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-022004 · doc1.xml · nonDerivative · entry 1 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,267 F1 · shares: On December 21, 2022, the reporting person and the Issuer determined to rescind 187,804 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer. F1 · price: On December 21, 2022, the reporting person and the Issuer determined to rescind 187,804 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer. Read SEC document |
| April 16, 2021 Filed Apr 16, 2021 20:53 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 187,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-008230 · doc1.xml · nonDerivative · entry 1 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,071 F1 · shares: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer. F1 · price: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer. Read SEC document |
| June 08, 2020 Filed Jun 12, 2020 21:45 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001654954-20-006584 · section16.xml · derivative · entry 2 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,038 Underlying: Common Stock · 40,000 shares Expires 2030-06-07 F2 · derivative.exercise_date: 100% vest on June 7, 2021, subject to the Grantee's continued service as a director on such dates. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 23:54 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-014535 · ownership.xml · nonDerivative · entry 1 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,663 F1 · price: These are restricted shares which vest on October 24, 2028, subject to earlier vesting in certain situations. F2 · balance_after: Aggregate amount indicated reflects 20-for-1 reverse split and includes additional 2,663 post-split restricted shares previously issued. Read SEC document |
| November 07, 2017 Filed Nov 10, 2017 00:02 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-17-011710 · f4110717donofrio_aytubio.xml · nonDerivative · entry 1 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,250 F1 · shares: These are restricted shares that vest on November 7, 2027, subject to earlier vesting in certain situations. F1 · price: These are restricted shares that vest on November 7, 2027, subject to earlier vesting in certain situations. F2 · balance_after: Of these shares, 3,250 are restricted shares that vest on July 12, 2026, subject to earlier vesting in certain situations. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:29 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 15,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000301 · doc4_4278.xml · derivative · entry 3 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-07-12 F3 · kind: These two transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 25% vests on September 30, 2016, December 31, 2016, March 31, 2017 and June 30, 2017, subject to the Grantee's continued service as a Director on such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:29 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 15,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000301 · doc4_4278.xml · derivative · entry 2 Donofrio John Jr. · CIK 0001679841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-07-12 F3 · kind: These two transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 25% vests on September 30, 2016, December 31, 2016, March 31, 2017 and June 30, 2017, subject to the Grantee's continued service as a Director on such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.